The contribution of naturally occurring polymorphisms in altering the biochemical and structural characteristics of HIV-1 subtype C protease

被引:31
作者
Coman, Roxana M. [1 ]
Robbins, Arthur H. [1 ]
Fernandez, Marty A. [1 ]
Gilliland, C. Taylor [1 ]
Sochet, Anthony A. [1 ]
Goodenow, Maureen M. [2 ]
McKenna, Robert [1 ]
Dunn, Ben M. [1 ]
机构
[1] Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA
[2] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA
关键词
D O I
10.1021/bi7018332
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Fourteen subtype B and C protease variants have been engineered in an effort to study whether the preexistent baseline polymorphisms, by themselves or in combination with drug resistance Mutations, differentially alter the biochemical and structural features of the subtype C protease when compared with those of subtype B protease. The kinetic studies performed in this work showed that the preexistent polymorphisms in Subtype C protease, by themselves, do not provide for a greater level of resistance. Inhibition analysis with eight clinically used protease inhibitors revealed that the natural polymorphisins found in subtype C protease, in combination with drug resistance mutations, can influence enzymatic catalytic efficiency and inhibitor resistance. Structural analyses of the subtype C protease bound to nelfinavir and indinavir showed that these inhibitors form similar interactions with the residues in the active site of subtype B and C proteases. It also revealed that the naturally occurring polymorphisms Could alter the position of the cuter loops of the subtype C protease, especially the 60's loop.
引用
收藏
页码:731 / 743
页数:13
相关论文
共 69 条
[1]  
Alexander CS, 2002, ANTIVIR THER, V7, P31
[2]   Impact of HIV type 1 genetic subtype on the outcome of antiretroviral therapy [J].
Atlas, A ;
Granath, F ;
Lindström, A ;
Lidman, K ;
Lindbäck, S ;
Alaeus, A .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2005, 21 (03) :221-227
[3]   Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir [J].
Baxter, John D. ;
Schapiro, Jonathan M. ;
Boucher, Charles A. B. ;
Kohlbrenner, Veronika M. ;
Hall, David B. ;
Scherer, Joseph R. ;
Mayers, Douglas L. .
JOURNAL OF VIROLOGY, 2006, 80 (21) :10794-10801
[4]   Chimeric aspartic proteinases and active site binding [J].
Bhatt, D ;
Dunn, BM .
BIOORGANIC CHEMISTRY, 2000, 28 (06) :374-393
[5]  
Bocket L, 2005, ANTIVIR THER, V10, P247
[6]   Crystallography & NMR system:: A new software suite for macromolecular structure determination [J].
Brunger, AT ;
Adams, PD ;
Clore, GM ;
DeLano, WL ;
Gros, P ;
Grosse-Kunstleve, RW ;
Jiang, JS ;
Kuszewski, J ;
Nilges, M ;
Pannu, NS ;
Read, RJ ;
Rice, LM ;
Simonson, T ;
Warren, GL .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1998, 54 :905-921
[7]   Low accumulation of L90M in protease from subtype FHIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism [J].
Calazans, A ;
Brindeiro, R ;
Brindeiro, P ;
Verli, H ;
Arruda, MB ;
Gonzalez, LMF ;
Guimaraes, JA ;
Diaz, RS ;
Antunes, OAC ;
Tanuri, A .
JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (11) :1961-1970
[8]   Resistance-associated mutations in the human immunodeficiency virus type 1 subtype C protease gene from treated and untreated patients in the United Kingdom [J].
Cane, PA ;
de Ruiter, A ;
Rice, P ;
Wiselka, M ;
Fox, R ;
Pillay, D .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (07) :2652-2654
[9]   Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in Brazilian patients failing HAART [J].
Caride, E ;
Hertogs, K ;
Larder, B ;
Dehertogh, P ;
Brindeiro, R ;
Machado, E ;
De Sá, CAM ;
Eyer-Silva, WA ;
Sion, FS ;
Passioni, LFC ;
Menezes, JA ;
Calazans, AR ;
Tanuri, A .
VIRUS GENES, 2001, 23 (02) :193-202
[10]   Analysis of HIV-1CRF_01 A/E protease inhibitor resistance: Structural determinants for maintaining sensitivity and developing resistance to atazanavir [J].
Clemente, JC ;
Coman, RM ;
Thiaville, MM ;
Janka, LK ;
Jeung, JA ;
Nukoolkarn, S ;
Govindasamy, L ;
Agbandje-McKenna, M ;
McKenna, R ;
Leelamanit, W ;
Goodenow, MM ;
Dunn, BM .
BIOCHEMISTRY, 2006, 45 (17) :5468-5477